BlackRock
LIMN

BlackRock’s Liminatus Pharma LIMN Stock Holding History

BlackRock’s Portfolio LIMN Stock Details LIMN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$35 Sell
313
-12,941
-98% -$2.23K ﹤0.01% 5646
2026
Q1 		$2.28K Sell
13,254
-1
-0% -$1 ﹤0.01% 5512
2025
Q4 		$8.09K Hold
13,255
– – ﹤0.01% 5303
2025
Q3 		$22.1K Hold
13,255
– – ﹤0.01% 5132
2025
Q2 		$148K Buy
+13,255
New +$149K ﹤0.01% 4741

Other funds holding LIMN

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SG
StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $12.2B AUM 47.93% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

BlackRock's LIMN Position: Q2 2026 in Review

BlackRock reduced its Liminatus Pharma (LIMN) stake by 98% in Q2 2026, selling an estimated $2.23K and leaving 313 shares worth $35. The position accounts for ﹤0.01% of the portfolio, ranked #5646.

BlackRock first reported a position in LIMN in Q2 2025 and has held it in 5 quarters since. The position peaked at $148K in Q2 2025. 9 funds tracked by Wall St. Rank hold LIMN as of Q2 2026.

  • BlackRock held 313 shares of Liminatus Pharma worth $35 as of Q2 2026.
  • BlackRock sold 12,941 Liminatus Pharma shares in Q2 2026, an estimated $2.23K.
  • Liminatus Pharma made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #5646 holding.
  • BlackRock first reported a position in Liminatus Pharma in Q2 2025 and has held it in 5 quarters since.
  • BlackRock's Liminatus Pharma position peaked at $148K in Q2 2025.
  • 9 funds tracked by Wall St. Rank held Liminatus Pharma as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.